Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Experiences Notable Increase in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) recently reported a notable increase in short interest during December. As of December 31st, the total short interest reached 6,000,000 shares, marking a 6.0% rise from the prior total of 5,660,000 shares on December 15th. With an average daily trading volume of 250,800 shares, the current days-to-cover ratio stands at 23.9 days, indicating a significant percentage of 31.2% of the company's stock is sold short.

Investment Changes by Large Investors

Institutional investors have been adjusting their stakes in Dianthus Therapeutics lately. Notably, Quest Partners LLC saw a substantial increase of 112,400.0% in their holdings during the third quarter, bringing their total to 1,125 shares now valued at about $31,000 after acquiring an additional 1,124 shares during this period. SG Americas Securities LLC increased its investment in Dianthus by 9.2% in the fourth quarter, now owning 9,653 shares worth approximately $210,000 after adding 814 shares. The Manufacturers Life Insurance Company entered a new investment in Dianthus during the second quarter, valued around $236,000. Additionally, Fred Alger Management LLC raised their stake by 52.5% in the third quarter, owning 9,633 shares valued at $264,000 following the purchase of 3,316 shares. Point72 DIFC Ltd also acquired a new position in the second quarter, estimated at $334,000. Currently, hedge funds and institutional investors collectively control about 47.53% of Dianthus Therapeutics’ stock.

Analyst Ratings and Price Targets

Shares of Dianthus Therapeutics have recently been reviewed by various analysts. TD Cowen initiated coverage with a "buy" rating on December 20th. Oppenheimer increased the target price from $48.00 to $52.00 while maintaining an "outperform" rating on November 11th. Raymond James upgraded Dianthus to a "moderate buy" in a research note on December 12th. HC Wainwright reaffirmed a "buy" rating with a $40.00 target in a report released on November 11th. Overall, there have been eight buy ratings and two strong buy ratings for the stock. According to MarketBeat.com, Dianthus Therapeutics holds an average rating of "Buy" with a projected price target of $46.43.

Dianthus Therapeutics Stock Performance

On Friday, Dianthus Therapeutics' stock rose by 4.1%, increasing by $0.79 to reach $20.00. The day's trading volume was 156,254 shares, which is lower than the average volume of 199,749. Currently, the company has a market capitalization of $592 million, a price-to-earnings (PE) ratio of -8.00, and a beta of 1.74. The stock’s 50-day moving average is $23.62, while the 200-day moving average is $26.40. Over the past year, Dianthus has seen a low of $10.65 and a high of $33.77.

Dianthus Therapeutics announced its most recent quarterly earnings on November 7th, where it reported earnings per share (EPS) of ($0.74), falling short of the analysts' expectations of ($0.59) by $0.15. The company has a remarkably negative net margin of 1,250.32% and a return on equity of -21.68%. For the quarter, Dianthus generated revenue of $2.17 million, exceeding the consensus estimate of $1.07 million. Analysts are projecting an EPS of -2.61 for the upcoming fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing complement therapeutics that target severe autoimmune and inflammatory diseases. The company is currently working on DNTH103, a monoclonal antibody undergoing Phase 2 clinical trials aimed at treating conditions such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Dianthus, Therapeutics, Investors